AMYLIN PHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY11 | FY10 | FY09 | FY08 | |
|---|---|---|---|---|
| Revenue | $650.7M | $668.8M | $758.4M | $769.6M |
| Operating income | −$491.5M | −$126.7M | −$173.3M | −$297.2M |
| Net income | −$37.3M | −$38.2M | −$186.3M | −$321.9M |
| Total assets | $1.87B | $1.53B | $1.73B | — |
| Total liabilities | — | — | — | — |
| Equity | −$138.7M | $343.5M | $422.5M | $519.3M |
| EPS (diluted) | — | $-1.06 | $-1.32 | $-2.35 |
| Shares out. | 144.4M | 144.1M | 141.7M | 137.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2011- Operating margin
- −75.5%
- Net margin
- −5.7%
- Return on equity
- 26.9%
- Return on assets
- −2.0%
- Return on capital (ROCE)
- −31.2%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-0.96
- Revenue growth (YoY)
- −2.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2011- Accruals / assets
- −6.7%clean
- Piotroski F-Score
- 3/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 3 good- Negative shareholder equity
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Strong return on equity (>15%)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- BYETTAOct 30, 2009
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Rowland Lloyd AOfficer — VP, Chief Compliance Officer | Aug 8, 2012 | J | 412 | $31.00 |
| Foletta Mark GOfficer — SVP, Chief Financial Officer | Aug 8, 2012 | J | 64,702 | $31.00 |
| Bradbury DanielOfficer — President & Chief Executive Of | Aug 8, 2012 | J | 215,526 | $31.00 |
| Lloyd Marcea BlandOfficer — SVP, Chief Administrative Offi | Aug 8, 2012 | J | 62,057.4 | $31.00 |
| Leonhardt Harry JOfficer — SVP, Legal, Compl & Corp Secty | Aug 8, 2012 | J | 32,344.5 | $31.00 |
| Marshall PaulOfficer — SVP, Operations | Aug 8, 2012 | J | 31,723 | $31.00 |
| Mihalik Vincent POfficer — SVP, Chief Commercial Officer | Aug 8, 2012 | J | 39,917 | $31.00 |
| Weyer ChristianOfficer — SVP, Research & Development | Aug 8, 2012 | J | 33,194.6 | $31.00 |
| Kolterman Orville GOfficer — SVP, Chief Medical Officer | Aug 8, 2012 | J | 71,349 | $31.00 |
| Gergen Mark JOfficer — SVP, Corporate Development | Aug 8, 2012 | U | 64,338.2 | $31.00 |
| Beck TeresaDirector | Aug 8, 2012 | J | 8,000 | $31.00 |
| Adams AdrianDirector | Aug 8, 2012 | J | 10,800 | $31.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · Debt acceleration / triggering event · Delisting / listing-standard notice · Unregistered equity sale · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsAug 13, 2012
- Entered a material agreementJul 3, 2012
- Other material eventJul 2, 2012
- Other material eventJun 18, 2012
- Other material eventJun 5, 2012
- Director / officer change · Shareholder voteMay 16, 2012
- Director / officer changeMay 15, 2012
- Results of operationsApr 26, 2012
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- CT ORDERFeb 21, 2014
- CT ORDERJan 7, 2014
- CT ORDERJan 7, 2014
- CT ORDERJan 7, 2014
- CT ORDERFeb 13, 2013
- CT ORDERNov 27, 2012
- CT ORDERSep 14, 2012
- EFFECTAug 21, 2012
- 15-12GFORM 15Aug 21, 2012
- S-8 POSPOST EFFECTIVE AMENDMENT TO S-8Aug 20, 2012
- S-8 POSPOST EFFECTIVE AMENDMENT TO S-8Aug 20, 2012
- S-8 POSPOST EFFECTIVE AMENDMENT TO S-8Aug 20, 2012
- S-8 POSPOST EFFECTIVE AMENDMENT TO S-8Aug 20, 2012
- S-8 POSPOST EFFECTIVE AMENDMENT TO S-8Aug 20, 2012
- S-8 POSPOST EFFECTIVE AMENDMENT TO S-8Aug 20, 2012
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.